首页 > 最新文献

Federal practitioner : for the health care professionals of the VA, DoD, and PHS最新文献

英文 中文
Equity and Inclusion in Military Recruitment: The Case for Neurodiversity in Uniform. 征兵工作中的公平与包容:穿军装的神经多样性案例。
Pub Date : 2023-12-01 Epub Date: 2023-12-15 DOI: 10.12788/fp.0447
Cynthia Geppert
{"title":"Equity and Inclusion in Military Recruitment: The Case for Neurodiversity in Uniform.","authors":"Cynthia Geppert","doi":"10.12788/fp.0447","DOIUrl":"10.12788/fp.0447","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 12","pages":"396-397"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thiazide Diuretic Utilization Within the VA. 退伍军人事务部内噻嗪类利尿剂的使用情况。
Pub Date : 2023-12-01 Epub Date: 2023-12-11 DOI: 10.12788/fp.0439
Kiana Green, Augustus Hough

Background: The 2017 American College of Cardiology/American Heart Association blood pressure guideline recommends chlorthalidone as the preferred thiazide diuretic. We aimed to better understand thiazide prescribing patterns within the US Department of Veterans Affairs (VA).

Methods: A retrospective analysis was conducted of patients with a prescription for hydrochlorothiazide (HCTZ), chlorthalidone, indapamide, or any combination products containing these from January 1, 2016, to January 21, 2022. The primary objective was to determine the utilization rates of each thiazide in the active cohort, assessed via χ2 test with Bonferroni correction. Secondary objectives included concomitant potassium or magnesium supplementation, blood pressure rates and control, and thiazide use from January 1, 2016, to December 31, 2021.

Results: Of 628,994 active thiazide prescriptions, utilization rates differed significantly between thiazide groups (P < .001). Rates for HCTZ, chlorthalidone, and indapamide were 84.6%, 14.9%, and 0.5%, respectively. HCTZ use decreased from 90.2% to 83.5% (P < .001) and chlorthalidone use increased from 9.3% to 16.0% (P < .001). Between thiazide groups, rates of blood pressure control were not significantly different (P = .58). Potassium or magnesium supplementation was significantly different between groups (P < .001). The highest concomitant supplementation was with indapamide followed by chlorthalidone and HCTZ with rates of 27.1%, 22.6%, and 12.4%, respectively.

Conclusions: Despite guideline recommendations for chlorthalidone, HCTZ is the most prescribed thiazide diuretic within the VA. However, there was a significant trend toward increased chlorthalidone prescribing from 2016 to 2021. Application of these data may guide further research to increase guideline-recommended therapy.

背景:2017 年美国心脏病学会/美国心脏协会血压指南推荐氯沙坦为首选噻嗪类利尿剂。我们旨在更好地了解美国退伍军人事务部(VA)的噻嗪类处方模式:我们对 2016 年 1 月 1 日至 2022 年 1 月 21 日期间开具氢氯噻嗪 (HCTZ)、氯沙利酮、吲哒帕胺或任何含有这些药物的复方产品处方的患者进行了回顾性分析。首要目标是确定活动队列中每种噻嗪类药物的使用率,通过χ2检验和Bonferroni校正进行评估。次要目标包括同时补充钾或镁,血压比率和控制,以及从 2016 年 1 月 1 日至 2021 年 12 月 31 日的噻嗪类药物使用情况:在 628,994 份有效噻嗪类药物处方中,不同噻嗪类药物组的使用率差异显著(P < .001)。HCTZ、氯沙利酮和吲哒帕胺的使用率分别为84.6%、14.9%和0.5%。HCTZ的使用率从90.2%降至83.5%(P < .001),氯塞酮的使用率从9.3%增至16.0%(P < .001)。噻嗪类药物组之间的血压控制率差异不大(P = .58)。钾或镁的补充在不同组间有显著差异(P < .001)。吲达帕胺的同时补充率最高,其次是氯沙坦和HCTZ,分别为27.1%、22.6%和12.4%:尽管指南推荐使用氯塞酮,但在退伍军人事务部,HCTZ仍是处方量最大的噻嗪类利尿剂。然而,从 2016 年到 2021 年,氯塞酮的处方量有明显增加的趋势。应用这些数据可指导进一步的研究,以增加指南推荐的疗法。
{"title":"Thiazide Diuretic Utilization Within the VA.","authors":"Kiana Green, Augustus Hough","doi":"10.12788/fp.0439","DOIUrl":"10.12788/fp.0439","url":null,"abstract":"<p><strong>Background: </strong>The 2017 American College of Cardiology/American Heart Association blood pressure guideline recommends chlorthalidone as the preferred thiazide diuretic. We aimed to better understand thiazide prescribing patterns within the US Department of Veterans Affairs (VA).</p><p><strong>Methods: </strong>A retrospective analysis was conducted of patients with a prescription for hydrochlorothiazide (HCTZ), chlorthalidone, indapamide, or any combination products containing these from January 1, 2016, to January 21, 2022. The primary objective was to determine the utilization rates of each thiazide in the active cohort, assessed via χ<sup>2</sup> test with Bonferroni correction. Secondary objectives included concomitant potassium or magnesium supplementation, blood pressure rates and control, and thiazide use from January 1, 2016, to December 31, 2021.</p><p><strong>Results: </strong>Of 628,994 active thiazide prescriptions, utilization rates differed significantly between thiazide groups (<i>P</i> < .001). Rates for HCTZ, chlorthalidone, and indapamide were 84.6%, 14.9%, and 0.5%, respectively. HCTZ use decreased from 90.2% to 83.5% (<i>P</i> < .001) and chlorthalidone use increased from 9.3% to 16.0% (<i>P</i> < .001). Between thiazide groups, rates of blood pressure control were not significantly different (<i>P</i> = .58). Potassium or magnesium supplementation was significantly different between groups (<i>P</i> < .001). The highest concomitant supplementation was with indapamide followed by chlorthalidone and HCTZ with rates of 27.1%, 22.6%, and 12.4%, respectively.</p><p><strong>Conclusions: </strong>Despite guideline recommendations for chlorthalidone, HCTZ is the most prescribed thiazide diuretic within the VA. However, there was a significant trend toward increased chlorthalidone prescribing from 2016 to 2021. Application of these data may guide further research to increase guideline-recommended therapy.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S6-S11"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increasing Local Productivity Through a Regional Antimicrobial Stewardship Collaborative. 通过地区抗菌药物管理协作提高当地生产力。
Pub Date : 2023-12-01 Epub Date: 2023-12-12 DOI: 10.12788/fp.0441
Morgan C Johnson, Jessica Bennett, Angela Kaucher, Kelly Davis, Milner Staub, Neena Thomas-Gosain

Background: Antimicrobial stewardship programs (ASPs) are vital to improving patient safety and ensuring quality of care but are often underresourced, limiting their effectiveness and reach. While barriers to ASP success have been well documented, approaches to address these barriers with limited resources are needed. Stewardship networks and collaboratives have emerged as possible solutions. In January 2020, 5 US Department of Veterans Affairs facilities created a regional ASP collaborative. In this article, we describe the impact of this collaborative on the productivity of the facilities' ASPs.

Methods: ASP annual reports for each of the 5 facilities provided retrospective data. Reports from fiscal year (FY) 2019 and reports from FY 2020-2022 were reviewed. Staffing, inpatient and outpatient stewardship reporting, individual and collaborative initiatives, and publications data were collected to measure productivity. Yearly results were trended for each facility and for the region. Additionally, the COVID-19 antibiotic use dashboard and upper respiratory infection dashboard were used to review the impact of initiatives on antibiotic prescribing during the collaborative.

Results: Regular reporting of outpatient metrics increased; 27% of measures showed improvement in 2019 and increased to 60% in 2022. For all 5 facilities, ASP initiatives increased from 33 in 2019 to 41 in 2022 (24% increase) with a corresponding increase in collaborative initiatives from 0 to 6. Likewise, publications increased from 2 in 2019 to 17 in 2022 (750% increase). Rates of reporting and improvement in inpatient metrics did not change significantly.

Conclusions: The ASP collaborative aided in efficiency and productivity within the region by sharing improvement practices, distributing workload for initiatives, and increasing publications.

背景:抗菌药物管理计划(ASP)对提高患者安全和确保护理质量至关重要,但往往资源不足,限制了其有效性和覆盖范围。尽管抗菌药物管理计划取得成功的障碍已被充分记录在案,但仍需要利用有限的资源来解决这些障碍。管理网络和协作已成为可能的解决方案。2020 年 1 月,美国退伍军人事务部的 5 家机构成立了地区性 ASP 合作组织。在本文中,我们将介绍该合作组织对设施内 ASP 生产率的影响:方法:5 家机构的 ASP 年度报告分别提供了回顾性数据。我们审查了 2019 财年的报告和 2020-2022 财年的报告。收集了人员配置、住院病人和门诊病人监管报告、个人和合作计划以及出版物数据,以衡量工作效率。对每个机构和整个地区的年度结果进行了趋势分析。此外,还使用 COVID-19 抗生素使用仪表板和上呼吸道感染仪表板来审查合作期间各项措施对抗生素处方的影响:结果:门诊指标的定期报告有所增加;2019 年有 27% 的指标有所改善,2022 年增至 60%。所有 5 家机构的 ASP 计划从 2019 年的 33 项增加到 2022 年的 41 项(增加 24%),合作计划也相应从 0 项增加到 6 项。同样,出版物也从 2019 年的 2 份增加到 2022 年的 17 份(增加了 750%)。住院病人指标的报告率和改进率没有显著变化:ASP 合作项目通过分享改进实践、分配项目工作量和增加出版物,提高了区域内的效率和生产力。
{"title":"Increasing Local Productivity Through a Regional Antimicrobial Stewardship Collaborative.","authors":"Morgan C Johnson, Jessica Bennett, Angela Kaucher, Kelly Davis, Milner Staub, Neena Thomas-Gosain","doi":"10.12788/fp.0441","DOIUrl":"10.12788/fp.0441","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial stewardship programs (ASPs) are vital to improving patient safety and ensuring quality of care but are often underresourced, limiting their effectiveness and reach. While barriers to ASP success have been well documented, approaches to address these barriers with limited resources are needed. Stewardship networks and collaboratives have emerged as possible solutions. In January 2020, 5 US Department of Veterans Affairs facilities created a regional ASP collaborative. In this article, we describe the impact of this collaborative on the productivity of the facilities' ASPs.</p><p><strong>Methods: </strong>ASP annual reports for each of the 5 facilities provided retrospective data. Reports from fiscal year (FY) 2019 and reports from FY 2020-2022 were reviewed. Staffing, inpatient and outpatient stewardship reporting, individual and collaborative initiatives, and publications data were collected to measure productivity. Yearly results were trended for each facility and for the region. Additionally, the COVID-19 antibiotic use dashboard and upper respiratory infection dashboard were used to review the impact of initiatives on antibiotic prescribing during the collaborative.</p><p><strong>Results: </strong>Regular reporting of outpatient metrics increased; 27% of measures showed improvement in 2019 and increased to 60% in 2022. For all 5 facilities, ASP initiatives increased from 33 in 2019 to 41 in 2022 (24% increase) with a corresponding increase in collaborative initiatives from 0 to 6. Likewise, publications increased from 2 in 2019 to 17 in 2022 (750% increase). Rates of reporting and improvement in inpatient metrics did not change significantly.</p><p><strong>Conclusions: </strong>The ASP collaborative aided in efficiency and productivity within the region by sharing improvement practices, distributing workload for initiatives, and increasing publications.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 12","pages":"412-417"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Pharmacists' Time Collecting Self-Monitoring Blood Glucose Data. 评估药剂师收集自我血糖监测数据的时间。
Pub Date : 2023-12-01 Epub Date: 2023-08-22 DOI: 10.12788/fp.0388
Cassie Perdew, Elaine Nguyen

Background: Patients on intensive insulin regimens are encouraged to self-monitor blood glucose (SMBG) to optimize their therapy. Clinical pharmacist practitioners (CPPs) use SMBG data to adjust diabetes medications; however, collecting SMBG data from patients is seen anecdotally as time intensive.

Methods: CPPs involved in diabetes management on primary care teams at the Boise Veterans Affairs Medical Center in Idaho were asked to estimate and record the following: SMBG data collection method, time spent collecting data, extra time spent documenting or formatting SMBG readings, total patient visit time, and visit type. For total patient visit time, pharmacists were asked to estimate only time spent discussing diabetes care and collecting SMBG data. Data were collected for 1 week using a standardized spreadsheet distributed to 24 CPPs.

Results: Eight pharmacists provided data from 120 patient encounters. For all encounters, the mean time spent collecting SMBG data was 3.3 minutes, and completing additional documentation/formatting was 1.3 minutes for a total of 4.6 minutes. Patient visits lasted a mean 20.1 minutes; 16% was spent on data collection and 6% on documentation and formatting.

Conclusions: At the Boise Veterans Affairs Medical Center, CPPs spend relatively little time per patient collecting SMBG data for clinical use. However, this time can be substantial when multiplied over several patient encounters. Opportunities exist to increase efficiency in SMBG data collection and documentation.

背景:我们鼓励接受胰岛素强化治疗的患者自我监测血糖 (SMBG),以优化治疗。临床药剂师(CPPs)利用 SMBG 数据来调整糖尿病药物;然而,从患者那里收集 SMBG 数据据说需要花费大量时间:方法:要求爱达荷州博伊西退伍军人事务医疗中心初级医疗团队中参与糖尿病管理的 CPP 估算并记录以下内容:SMBG 数据收集方法、用于收集数据的时间、用于记录或格式化 SMBG 读数的额外时间、患者就诊总时间以及就诊类型。对于访问患者的总时间,药剂师只需估计讨论糖尿病护理和收集 SMBG 数据所花费的时间。使用分发给 24 位 CPP 的标准化电子表格收集了为期一周的数据:结果:8 位药剂师提供了 120 次患者就诊的数据。在所有会诊中,收集 SMBG 数据的平均时间为 3.3 分钟,完成其他文档/格式化的平均时间为 1.3 分钟,总计 4.6 分钟。患者就诊时间平均为 20.1 分钟;其中 16% 用于收集数据,6% 用于记录和格式化:在博伊西退伍军人事务医疗中心,CPP 为每位患者收集用于临床的 SMBG 数据所花费的时间相对较少。但是,如果将这一时间乘以多个病人的就诊时间,时间就会非常可观。提高 SMBG 数据收集和记录效率的机会是存在的。
{"title":"Evaluating Pharmacists' Time Collecting Self-Monitoring Blood Glucose Data.","authors":"Cassie Perdew, Elaine Nguyen","doi":"10.12788/fp.0388","DOIUrl":"10.12788/fp.0388","url":null,"abstract":"<p><strong>Background: </strong>Patients on intensive insulin regimens are encouraged to self-monitor blood glucose (SMBG) to optimize their therapy. Clinical pharmacist practitioners (CPPs) use SMBG data to adjust diabetes medications; however, collecting SMBG data from patients is seen anecdotally as time intensive.</p><p><strong>Methods: </strong>CPPs involved in diabetes management on primary care teams at the Boise Veterans Affairs Medical Center in Idaho were asked to estimate and record the following: SMBG data collection method, time spent collecting data, extra time spent documenting or formatting SMBG readings, total patient visit time, and visit type. For total patient visit time, pharmacists were asked to estimate only time spent discussing diabetes care and collecting SMBG data. Data were collected for 1 week using a standardized spreadsheet distributed to 24 CPPs.</p><p><strong>Results: </strong>Eight pharmacists provided data from 120 patient encounters. For all encounters, the mean time spent collecting SMBG data was 3.3 minutes, and completing additional documentation/formatting was 1.3 minutes for a total of 4.6 minutes. Patient visits lasted a mean 20.1 minutes; 16% was spent on data collection and 6% on documentation and formatting.</p><p><strong>Conclusions: </strong>At the Boise Veterans Affairs Medical Center, CPPs spend relatively little time per patient collecting SMBG data for clinical use. However, this time can be substantial when multiplied over several patient encounters. Opportunities exist to increase efficiency in SMBG data collection and documentation.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S12-S15"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Multidisciplinary Transitional Pain Service on Health Care Use and Costs Following Orthopedic Surgery. 多学科过渡性疼痛服务对骨科手术后医疗使用和成本的影响。
Pub Date : 2023-12-01 Epub Date: 2023-12-12 DOI: 10.12788/fp.0438
Minkyoung Yoo, Michael J Buys, Richard E Nelson, Shardool Patel, Kimberlee M Bayless, Zachary Anderson, Julie B Hales, Benjamin S Brooke

Background: Opioid use disorder is a significant cause of morbidity, mortality, and health care costs. A transitional pain service (TPS) approach to perioperative pain management has been shown to reduce opioid use among patients undergoing orthopedic joint surgery. However, whether TPS also leads to lower health care use and costs is unknown.

Methods: We designed this study to estimate the effect of TPS implementation relative to standard care on health care use and associated costs of care following orthopedic surgery. We evaluated postoperative health care use and costs for patients who underwent orthopedic joint surgery at 6 US Department of Veterans Affairs medical centers (VAMCs) between 2018 and 2019 using difference-in-differences analysis. Patients enrolled in the TPS at the Salt Lake City VAMC were matched to control patients undergoing the same surgeries at 5 different VAMCs without a TPS. We stratified patients based on history of preoperative opioid use into chronic opioid use (COU) and nonopioid use (NOU) groups and analyzed them separately.

Results: For NOU patients, TPS was associated with a mean increase in the number of outpatient visits (6.9 visits; P < .001), no change in outpatient costs, and a mean decrease in inpatient costs (-$12,170; P = .02) during the 1-year follow-up period. TPS was not found to increase health care use or costs for COU patients.

Conclusions: Although TPS led to an increase in outpatient visits for NOU patients, there was no increase in outpatient costs and a decrease in inpatient costs after orthopedic surgery. Further, there was no added cost for managing COU patients with a TPS. These findings suggest that TPS can be implemented to reduce opioid use following joint surgery without increasing health care costs.

背景:阿片类药物使用障碍是导致发病率、死亡率和医疗费用的一个重要原因。围手术期疼痛管理的过渡性疼痛服务(TPS)方法已被证明可减少骨科关节手术患者阿片类药物的使用。然而,过渡性疼痛服务是否也能降低医疗服务的使用量和成本尚不清楚:我们设计了这项研究,旨在估算相对于标准护理,TPS 的实施对骨科手术后医疗护理使用和相关护理成本的影响。我们采用差异分析法评估了 2018 年至 2019 年期间在美国退伍军人事务部 6 个医疗中心(VAMC)接受骨科关节手术的患者的术后医疗使用情况和成本。在盐湖城退伍军人医疗中心加入 TPS 的患者与在 5 个不同的未加入 TPS 的退伍军人医疗中心接受相同手术的对照组患者进行了配对。我们根据术前阿片类药物使用史将患者分为慢性阿片类药物使用组(COU)和非阿片类药物使用组(NOU),并分别进行分析:对于非阿片类药物滥用患者,TPS 与门诊就诊次数平均增加(6.9 次;P < .001)、门诊费用无变化以及随访 1 年期间住院费用平均减少(-12,170 美元;P = .02)有关。TPS 并未增加 COU 患者的医疗费用:结论:虽然 TPS 增加了 NOU 患者的门诊次数,但骨科手术后的门诊费用并未增加,住院费用也有所下降。此外,使用 TPS 管理 COU 患者也不会增加成本。这些研究结果表明,实施 TPS 可以减少关节手术后阿片类药物的使用,同时不会增加医疗成本。
{"title":"Effect of Multidisciplinary Transitional Pain Service on Health Care Use and Costs Following Orthopedic Surgery.","authors":"Minkyoung Yoo, Michael J Buys, Richard E Nelson, Shardool Patel, Kimberlee M Bayless, Zachary Anderson, Julie B Hales, Benjamin S Brooke","doi":"10.12788/fp.0438","DOIUrl":"10.12788/fp.0438","url":null,"abstract":"<p><strong>Background: </strong>Opioid use disorder is a significant cause of morbidity, mortality, and health care costs. A transitional pain service (TPS) approach to perioperative pain management has been shown to reduce opioid use among patients undergoing orthopedic joint surgery. However, whether TPS also leads to lower health care use and costs is unknown.</p><p><strong>Methods: </strong>We designed this study to estimate the effect of TPS implementation relative to standard care on health care use and associated costs of care following orthopedic surgery. We evaluated postoperative health care use and costs for patients who underwent orthopedic joint surgery at 6 US Department of Veterans Affairs medical centers (VAMCs) between 2018 and 2019 using difference-in-differences analysis. Patients enrolled in the TPS at the Salt Lake City VAMC were matched to control patients undergoing the same surgeries at 5 different VAMCs without a TPS. We stratified patients based on history of preoperative opioid use into chronic opioid use (COU) and nonopioid use (NOU) groups and analyzed them separately.</p><p><strong>Results: </strong>For NOU patients, TPS was associated with a mean increase in the number of outpatient visits (6.9 visits; <i>P</i> < .001), no change in outpatient costs, and a mean decrease in inpatient costs (-$12,170; <i>P</i> = .02) during the 1-year follow-up period. TPS was not found to increase health care use or costs for COU patients.</p><p><strong>Conclusions: </strong>Although TPS led to an increase in outpatient visits for NOU patients, there was no increase in outpatient costs and a decrease in inpatient costs after orthopedic surgery. Further, there was no added cost for managing COU patients with a TPS. These findings suggest that TPS can be implemented to reduce opioid use following joint surgery without increasing health care costs.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 12","pages":"418-425"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary Artery Bypass Graft Saphenous Vein Harvest Site Hyperpigmentation. 冠状动脉旁路移植隐静脉采集部位色素沉着。
Pub Date : 2023-12-01 Epub Date: 2023-12-14 DOI: 10.12788/fp.0435
Katelyn J Rypka, Sophie M Cronk, Travis Fulk, Anne-Marie Leuck, Noah Goldfarb
{"title":"Coronary Artery Bypass Graft Saphenous Vein Harvest Site Hyperpigmentation.","authors":"Katelyn J Rypka, Sophie M Cronk, Travis Fulk, Anne-Marie Leuck, Noah Goldfarb","doi":"10.12788/fp.0435","DOIUrl":"10.12788/fp.0435","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 Suppl 6","pages":"S31-S32"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Kidney Disease and Military Service in US Adults, 1999-2018. 1999-2018 年美国成年人中的慢性肾病和兵役情况。
Pub Date : 2023-12-01 Epub Date: 2023-12-17 DOI: 10.12788/fp.0445
Scott Reule, Kristine Ensrud, Jaeden Danko, Donal Sexton, Laura Siegle, Areef Ishani, Craig Solid, Robert Foley

Background: Although the management of chronic kidney disease (CKD) has changed considerably in US adults, it is uncertain whether the burden, risk factors, and temporal trends of CKD are similar regarding prior military service.

Methods: This observational study used National Health and Nutrition Examination Survey data to quantify the association between CKD and military service in a generalizable sample of US adults between 1999 and 2018.

Results: The respective frequencies (standard error [SE]) of CKD and military service were 15.2% (0.3) and 11.5% (0.3). The proportion (SE) with CKD was significantly higher among those with prior MS vs the overall population (22.7% [0.7] vs 15.2% [0.3]; P < .001). Within the military service population, the proportion (SE) with CKD differed by era: 1999 to 2002, 18.9% (1.1); 2003 to 2006, 24.9% (1.5); 2007 to 2010, 22.3% (1.5); 2011 to 2014, 24.3% (1.7); and 2015 to 2018, 24.0% (1.8) (P = .02). Following adjustment for age, sex, and race and ethnicity, prior military service was associated (P < .05) with a higher likelihood of CKD (adjusted odds ratio, 1.17; 95% CI 1.06-1.28). Adjusted associations of CKD differed in groups with and without military service for the 40 to 64 years age group, ≥ 65 years age group, female sex, and family poverty (P < .05 vs variable-specific reference category).

Conclusions: Military service is associated with a higher likelihood of CKD in US adults. Risk factors for CKD differed among many subgroups both with and without military service history. Future research is needed to better determine whether military service constitutes a unique risk factor for CKD.

背景:尽管美国成年人慢性肾脏病(CKD)的管理发生了很大变化,但目前尚不确定慢性肾脏病的负担、风险因素和时间趋势是否与服兵役前相似:这项观察性研究利用全国健康与营养调查数据,在 1999 年至 2018 年间对美国成年人的可普及样本进行了量化,以确定 CKD 与服兵役之间的关联:CKD和服兵役的频率(标准误差[SE])分别为15.2%(0.3)和11.5%(0.3)。与总体人群相比,曾患多发性硬化症的人群中患有慢性肾脏病的比例(SE)明显更高(22.7% [0.7] vs 15.2% [0.3];P < .001)。在军队服役人群中,患有慢性肾脏病的比例(SE)因年代而异:1999 年至 2002 年,18.9% (1.1);2003 年至 2006 年,24.9% (1.5);2007 年至 2010 年,22.3% (1.5);2011 年至 2014 年,24.3% (1.7);2015 年至 2018 年,24.0% (1.8) (P = .02)。在对年龄、性别、种族和民族进行调整后,曾服兵役者患慢性肾脏病的可能性更高(P < .05)(调整后的几率比为 1.17;95% CI 为 1.06-1.28)。在 40 至 64 岁年龄组、≥ 65 岁年龄组、女性和家庭贫困人群中,有兵役和没有兵役的人群患慢性肾脏病的调整后相关性不同(P < .05 vs 变量特定参考类别):结论:服兵役与美国成年人患慢性肾脏病的可能性较高有关。无论是有服兵役史还是没有服兵役史,许多亚群的 CKD 风险因素都有所不同。未来的研究需要更好地确定服兵役是否是导致慢性肾脏病的独特风险因素。
{"title":"Chronic Kidney Disease and Military Service in US Adults, 1999-2018.","authors":"Scott Reule, Kristine Ensrud, Jaeden Danko, Donal Sexton, Laura Siegle, Areef Ishani, Craig Solid, Robert Foley","doi":"10.12788/fp.0445","DOIUrl":"10.12788/fp.0445","url":null,"abstract":"<p><strong>Background: </strong>Although the management of chronic kidney disease (CKD) has changed considerably in US adults, it is uncertain whether the burden, risk factors, and temporal trends of CKD are similar regarding prior military service.</p><p><strong>Methods: </strong>This observational study used National Health and Nutrition Examination Survey data to quantify the association between CKD and military service in a generalizable sample of US adults between 1999 and 2018.</p><p><strong>Results: </strong>The respective frequencies (standard error [SE]) of CKD and military service were 15.2% (0.3) and 11.5% (0.3). The proportion (SE) with CKD was significantly higher among those with prior MS vs the overall population (22.7% [0.7] vs 15.2% [0.3]; <i>P</i> < .001). Within the military service population, the proportion (SE) with CKD differed by era: 1999 to 2002, 18.9% (1.1); 2003 to 2006, 24.9% (1.5); 2007 to 2010, 22.3% (1.5); 2011 to 2014, 24.3% (1.7); and 2015 to 2018, 24.0% (1.8) (<i>P =</i> .02). Following adjustment for age, sex, and race and ethnicity, prior military service was associated (<i>P</i> < .05) with a higher likelihood of CKD (adjusted odds ratio, 1.17; 95% CI 1.06-1.28). Adjusted associations of CKD differed in groups with and without military service for the 40 to 64 years age group, ≥ 65 years age group, female sex, and family poverty (<i>P</i> < .05 vs variable-specific reference category).</p><p><strong>Conclusions: </strong>Military service is associated with a higher likelihood of CKD in US adults. Risk factors for CKD differed among many subgroups both with and without military service history. Future research is needed to better determine whether military service constitutes a unique risk factor for CKD.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 12","pages":"404-411"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The VA Research Enterprise: A Platform for National Partnerships Toward Evidence Building and Scientific Innovation VA研究企业:建立证据和科学创新的国家合作平台
Amanda P Garcia
{"title":"The VA Research Enterprise: A Platform for National Partnerships Toward Evidence Building and Scientific Innovation","authors":"Amanda P Garcia","doi":"10.12788/fp.0425","DOIUrl":"https://doi.org/10.12788/fp.0425","url":null,"abstract":"","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"137 1-2","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135270816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How VA Innovative Partnerships and Health Care Systems Can Respond to National Needs: NOSE Trial Example VA创新伙伴关系和医疗保健系统如何响应国家需求:NOSE试验实例
Joseph Iaquinto
Background: At the onset of COVID-19, essential supplies were not obtainable from manufacturers. This caused patients and clinicians to have additional risk and exposure to COVID-19 in some settings and the wasting of critical materials when testing was unavailable in other settings. Observations: The Veterans Health Administration (VHA) developed and enacted contingency plans for depleted supplies under both its First Mission—to care for veterans—and its Fourth Mission— to support the American health care system in times of crisis. A partnership among the VHA, US Food and Drug Administration, the National Institutes of Health, and America Makes addressed national shortages with the curation and development of designs, testing protocols, product evaluation, and product validation. VHA leveraged digital manufacturing to produce nasopharyngeal swabs onsite—3-dimensional-printed nasal swabs—and validate them to cover the gap between stockpile depletion and ramp up of traditional product manufacturing. Conclusions: This effort involved close collaboration between innovators and researchers within the organization and alongside government, industry, and academic partners. We illustrate this collaborative concept here with a use case of nasal swabs to demonstrate successes and lessons learned that are shaping how the VHA in conjunction with government and industry partners can shepherd this new strategy for crisis preparedness.
{"title":"How VA Innovative Partnerships and Health Care Systems Can Respond to National Needs: NOSE Trial Example","authors":"Joseph Iaquinto","doi":"10.12788/fp.0418","DOIUrl":"https://doi.org/10.12788/fp.0418","url":null,"abstract":"Background: At the onset of COVID-19, essential supplies were not obtainable from manufacturers. This caused patients and clinicians to have additional risk and exposure to COVID-19 in some settings and the wasting of critical materials when testing was unavailable in other settings. Observations: The Veterans Health Administration (VHA) developed and enacted contingency plans for depleted supplies under both its First Mission—to care for veterans—and its Fourth Mission— to support the American health care system in times of crisis. A partnership among the VHA, US Food and Drug Administration, the National Institutes of Health, and America Makes addressed national shortages with the curation and development of designs, testing protocols, product evaluation, and product validation. VHA leveraged digital manufacturing to produce nasopharyngeal swabs onsite—3-dimensional-printed nasal swabs—and validate them to cover the gap between stockpile depletion and ramp up of traditional product manufacturing. Conclusions: This effort involved close collaboration between innovators and researchers within the organization and alongside government, industry, and academic partners. We illustrate this collaborative concept here with a use case of nasal swabs to demonstrate successes and lessons learned that are shaping how the VHA in conjunction with government and industry partners can shepherd this new strategy for crisis preparedness.","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"60 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135271097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Who Gets to Determine Whether Home Is "Unsafe" at the End of Life? 谁来决定生命终结时房屋是否 "不安全"?
Pub Date : 2023-11-01 Epub Date: 2023-11-09 DOI: 10.12788/fp.0434
Jessica X Zuo, Andrea Ruskin, Margaret R Bauer

Background: At the end of life, some patients wish to be discharged directly home from the hospital, but health care teams may consider this unsafe, raising concerns for capacity and risk. However, defining risk is subjective and impacted by values, preferences, and clinical status. Accommodating patient preferences in discharge destinations can promote autonomy, dignity, and quality of life at the end of life.

Observations: We developed a risk assessment framework to help clinicians objectively identify risk factors and protective factors and develop a comprehensive discharge plan. We applied this framework to a veteran nearing the end of life and he was able to successfully return home from the hospital.

Conclusions: Approaching end-of-life discharges with a framework can inform discharge planning and lessen the risk of adverse events. Importantly, this framework can help clinicians communicate better and partner with patients and their loved ones in prioritizing patient values and preferences.

背景:在生命的最后阶段,有些病人希望直接出院回家,但医疗团队可能会认为这不安全,从而引发对能力和风险的担忧。然而,风险的定义是主观的,并受到价值观、偏好和临床状态的影响。在出院目的地方面照顾到患者的偏好可以促进自主性、尊严和生命末期的生活质量:我们开发了一个风险评估框架,帮助临床医生客观地识别风险因素和保护因素,并制定全面的出院计划。我们将这一框架应用于一名临近生命终点的退伍军人,他成功地从医院返回家中:结论:使用该框架处理生命末期出院问题可为出院计划提供依据,并降低不良事件发生的风险。重要的是,该框架可以帮助临床医生更好地与患者及其亲人沟通和合作,优先考虑患者的价值观和偏好。
{"title":"Who Gets to Determine Whether Home Is \"Unsafe\" at the End of Life?","authors":"Jessica X Zuo, Andrea Ruskin, Margaret R Bauer","doi":"10.12788/fp.0434","DOIUrl":"https://doi.org/10.12788/fp.0434","url":null,"abstract":"<p><strong>Background: </strong>At the end of life, some patients wish to be discharged directly home from the hospital, but health care teams may consider this unsafe, raising concerns for capacity and risk. However, defining risk is subjective and impacted by values, preferences, and clinical status. Accommodating patient preferences in discharge destinations can promote autonomy, dignity, and quality of life at the end of life.</p><p><strong>Observations: </strong>We developed a risk assessment framework to help clinicians objectively identify risk factors and protective factors and develop a comprehensive discharge plan. We applied this framework to a veteran nearing the end of life and he was able to successfully return home from the hospital.</p><p><strong>Conclusions: </strong>Approaching end-of-life discharges with a framework can inform discharge planning and lessen the risk of adverse events. Importantly, this framework can help clinicians communicate better and partner with patients and their loved ones in prioritizing patient values and preferences.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"40 11","pages":"368-372"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1